サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1373877

創薬におけるAIの世界市場 - 市場規模、シェア、成長分析：タイプ別、エンドユーザー別 - 業界予測（2023年～2030年）

Global AI in Drug Discovery Market Size, Share, Growth Analysis, By Type(Small molecules and Large molecules), By End-User(Pharmaceutical and Biotechnology Companies and Academics and Research institutes) - Industry Forecast 2023-2030
出版日: | 発行: SkyQuest | ページ情報: 英文 157 Pages | 納期: 3～5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
創薬におけるAIの世界市場 - 市場規模、シェア、成長分析：タイプ別、エンドユーザー別 - 業界予測（2023年～2030年）
出版日: 2023年10月17日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日
  • 全表示
  • 概要
  • 目次
概要

世界の創薬におけるAIの市場規模は2021年に8億5,000万米ドル、2022年に11億160万米ドルとなりました。同市場は、予測期間中（2023年～2030年）に29.6%のCAGRで拡大し、2030年には49億8,280万米ドルに成長する見通しです。

世界の創薬におけるAI市場は、人工知能（AI）と機械学習（ML）の力を従来の医薬品研究開発プロセスに融合させた、急速に進化・変革する分野です。AIは、新薬の発見・開発を加速し、臨床試験を最適化し、患者の転帰を改善する革新的なソリューションを提供することで、創薬プロセスに革命をもたらしています。創薬におけるAIは、計算アルゴリズムと高度なデータ解析を活用して、大量の生物学的・化学的データを分析します。これにより、研究者は潜在的な創薬標的を特定し、新規分子を設計し、その特性を予測し、安全性と有効性を評価することができます。AIを活用することで、製薬会社や研究機関は創薬プロセスを合理化し、コストを削減し、新薬の上市成功率を高めることができます。世界の創薬におけるAI市場は、製薬会社、テクノロジー企業、ベンチャーキャピタルから大きな成長と投資を目の当たりにしています。市場を牽引しているのは、革新的で効果的な医薬品に対する需要の高まり、ライフサイエンス業界におけるビッグデータの利用可能性の拡大、AIやML技術の進歩といった要因です。さらに、規制当局は創薬におけるAIの可能性を認識しつつあり、その導入に向けたガイドラインや枠組みの確立に積極的に取り組んでいます。

世界中で、慢性疾患の有病率が急速に上昇しています。米国疾病予防管理センター（CDC）は、米国では10人中6人が慢性疾患にかかっていると予測されています。CDCはまた、糖尿病や心臓病などの慢性疾患が米国における主な死因であることを強調しています。これらの数字は、慢性疾患の罹患率の上昇と、これらの疾患によってもたらされる死亡率の減少の必要性を強調しています。様々な慢性疾患を治療し、重症度を軽減するための薬剤の特定に関する洞察を得ることは、薬剤研究に利用されるAIプラットフォームを利用した実用的な代替案であるとみられています。

当レポートは、世界の創薬におけるAI市場について調査し、市場の概要とともに、タイプ別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

親市場分析

市場規模

  • 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題

主要な市場の洞察

  • 技術分析
  • 価格分析
  • サプライチェーン分析
  • バリューチェーン分析
  • 市場のエコシステム
  • IP分析
  • 動向分析
  • スタートアップ分析
  • 原材料分析
  • イノベーションマトリックス
  • パイプライン製品分析
  • マクロ経済指標
  • トップ投資分析
  • 主な成功要因
  • 競合の程度

市場力学と見通し

  • 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
  • 規制状況
  • ポーター分析

世界の創薬におけるAI市場、タイプ別

  • 市場概要
  • 低分子、高分子

世界の創薬におけるAI市場、エンドユーザー別

  • 市場概要
  • 製薬会社・バイオテクノロジー企業および学術研究機関

世界の創薬におけるAI市場、地域別

  • 市場概要
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

競合情勢

  • 主要企業プロファイル
    • IBM Corporation
    • Google LLC
    • Microsoft Corporation
    • NVIDIA Corporation
    • Insilico Medicine
    • BenevolentAI Ltd
    • Exscientia Ltd
    • Atomwise Inc
    • Berg LLC
    • XtalPi Inc
    • Numerate Inc
    • Cyclica Inc
    • Envisagenics Inc
    • BioXcel Therapeutics Inc
    • Recursion Pharmaceuticals Inc
    • Atomwise Inc
    • Healx Ltd
    • Cloud Pharmaceuticals Inc
    • TwoXAR Incorporated
    • Cerebras Systems Inc
目次
Product Code: SQMIG35J2061

Global AI in Drug Discovery Market size was valued at USD 850 million in 2021 and is poised to grow from USD 1,101.6 million in 2022 to USD 4,982.8 million by 2030, growing at a CAGR of 29.6% during the forecast period (2023-2030).

The global AI in drug discovery market is a rapidly evolving and transformative field that combines the power of artificial intelligence (AI) and machine learning (ML) with traditional pharmaceutical research and development processes. AI is revolutionizing the drug discovery process by offering innovative solutions to accelerate the discovery and development of new drugs, optimize clinical trials, and improve patient outcomes. AI in drug discovery leverages computational algorithms and advanced data analytics to analyze massive amounts of biological and chemical data. It enables researchers to identify potential drug targets, design novel molecules, predict their properties, and assess their safety and efficacy. By utilizing AI, pharmaceutical companies and research institutions can streamline the drug discovery process, reduce costs, and increase the success rate of bringing new drugs to market. The global AI in drug discovery market is witnessing significant growth and investment from pharmaceutical companies, technology firms, and venture capitalists. The market is driven by factors such as the increasing demand for innovative and effective drugs, the growing availability of big data in the life sciences industry, and advancements in AI and ML technologies. Furthermore, regulatory agencies are increasingly recognizing the potential of AI in drug discovery and are actively working to establish guidelines and frameworks for its implementation.

Top-down and bottom-up approaches were used to estimate and validate the size of the global AI In Drug Discovery Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global AI In Drug Discovery Market Segmental Analysis

Global AI in Drug Discovery Market is segmented type, end-user, and region. Based on Technology, the market can be segmented into small molecules and large molecules. Based on end-user, the market is segmented into Pharmaceutical and Biotechnology Companies and Academics and Research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global AI In Drug Discovery Market Dynamics

Drivers of the Global AI In Drug Discovery Market

Rise in incidence of chronic diseases propels need for AI in drug discovery

Around the world, the prevalence of chronic diseases is rising quickly. The Centres for Disease Control and Prevention (CDC) estimate that six out of ten persons in the United States have a chronic illness. The CDC also emphasises that chronic illnesses like diabetes and heart disease are the main killers in the United States. These figures highlight the rising incidence of chronic diseases and the necessity of reducing the death rate brought on by these illnesses. Deriving insights into the identification of medications to treat and lessen the severity of various chronic diseases may show to be a practical alternative using AI platforms utilised for drug research.

Restraints in the Global AI In Drug Discovery Market

High cost associated with technology and technical limitations

The healthcare industry currently faces a number of difficult problems, such as rising medicine and therapy costs, and society needs specific, significant improvements in this area. Since this data are utilised for the following training that is given to the system, the success of AI as a whole hinges on their availability. For a business, accessing data from different database providers may result in additional expenses. Clinical trials take six to seven years to complete and include a substantial monetary investment in order to determine the safety and effectiveness of a medicinal product in people for a specific disease condition. Only one out of every ten compounds that undergo these trials, however, receive successful clearance, which represents a significant loss for the industry.

Market Trends of Global AI In Drug Discovery Key

The global AI in drug discovery market is characterized by several key market trends that are shaping the industry's landscape. Firstly, there is an increasing adoption of AI technologies as pharmaceutical companies recognize their potential in analyzing complex biological and chemical data. By leveraging AI capabilities, drug discovery processes are becoming more efficient and successful. Collaborations and partnerships are on the rise in AI in drug discovery market. Pharmaceutical companies, technology firms, and academic institutions are joining forces to combine expertise and resources. These collaborations accelerate innovation and knowledge sharing, leading to advancements in AI-driven drug discovery. Overall, these key market trends highlight the transformative impact of AI in drug discovery. By enhancing efficiency, precision, and personalized medicine approaches, AI technologies are shaping the future of pharmaceutical research and development.

Table of Contents

  • Executive Summary
    • Market Overview
    • Wheel of Fortune
  • Research Methodology
    • Information Procurement
    • Secondary & Primary Data Sources
    • Market Size Estimation
    • Market Assumptions & Limitations
  • Parent Market Analysis
    • Market Overview
    • Market Size
    • Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
  • Key Market Insights
    • Technology Analysis
    • Pricing Analysis
    • Supply Chain Analysis
    • Value Chain Analysis
    • Ecosystem of the Market
    • IP Analysis
    • Trade Analysis
    • Startup Analysis
    • Raw Material Analysis
    • Innovation Matrix
    • Pipeline Product Analysis
    • Macroeconomic Indicators
    • Top Investment Analysis
    • Key Success Factor
    • Degree of Competition
  • Market Dynamics & Outlook
    • Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
    • Regulatory Landscape
    • Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
    • Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact
  • Global AI in Drug Discovery Market by Type
    • Market Overview
    • Small molecules and Large molecules
  • Global AI in Drug Discovery Market by End-User
    • Market Overview
    • Pharmaceutical and Biotechnology Companies and Academics and Research institutes
  • Global AI in Drug Discovery Market Size by Region
    • Market Overview
    • North America
  • USA
  • Canada
    • Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
    • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
    • Latin America
  • Brazil
  • Rest of Latin America
    • Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA
  • Competitive Landscape
    • Top 5 Player Comparison
    • Market Positioning of Key Players, 2021
    • Strategies Adopted by Key Market Players
    • Top Winning Strategies
  • By Development
  • By Company
  • By Year
    • Recent Activities in the Market
    • Key Companies Market Share (%), 2021
  • Key Company Profiles
    • IBM Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Google LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Microsoft Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • NVIDIA Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Insilico Medicine (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • BenevolentAI Ltd (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Exscientia Ltd (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Atomwise Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Berg LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • XtalPi Inc (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Numerate Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Cyclica Inc (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Envisagenics Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • BioXcel Therapeutics Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Recursion Pharmaceuticals Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Atomwise Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Healx Ltd (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Cloud Pharmaceuticals Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • TwoXAR Incorporated (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Cerebras Systems Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments